Research programme: DNA gyrase inhibitors - PfizerAlternative Names: 2-Hydroxyisoquinolones research programme - Pfizer; DNA gyrase inhibitors research programme - Pfizer; Research programme: 2-hydroxyisoquinolones - Pfizer
Latest Information Update: 23 Jul 2002
At a glance
- Originator Pfizer
- Mechanism of Action DNA gyrase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Oct 2000 Preclinical development for Bacterial infections in USA (Unknown route)